Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

The promise of tumor immunotherapy to significantly improve survival in patients who are
refractory to long-standing therapies, such as chemotherapy and radiation, is now being …

Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a
popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed …

Abstract Purpose of Review Immunotherapy has emerged as a promising cancer treatment;
however, success in only select clinical indications underscores the need for novel …

Listeria monocytogenes is a facultative intracellular gram‐positive bacterium that naturally
infects professional antigen presenting cells (APC) to target antigens to both class I and …

Introduction: The development of an effective therapeutic vaccine to induce cancer-specific
immunity remains problematic. Recently, a species of intracellular pathogen known as …

For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …

As a facultative intracellular bacterium, Listeria monocytogenes has adapted to live within
the cytosol of the host cell. It is actively taken up by antigen-presenting cells through …

Because of its cytosolic localization, Listeria monocytogenes (LM) has long been considered
an attractive tool for delivering tumor-associated antigens (TAA) antigens in vivoto combat …

Active immunotherapy targeting dendritic cells (DCs) has shown great promise in preclinical
models and in human clinical trials for the treatment of malignant disease. Sipuleucel-T …